Johnson & Johnson (JNJ) Announces SPRAVATO Approved in the U.S.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Raymond James Reiterates Outperform Rating on Johnson & Johnson (JNJ)
January 22, 2025 8:15 AM ESTRaymond James analyst Jayson Bedford reiterated an Outperform rating and $170.00 price target on Johnson & Johnson (NYSE: JNJ)
The analyst comments "Quick take: 4Q results were solid with a 1% revenue beat and a 3% EPS beat. The revenue upside was driven by Innovative Medicine... More
